What's in Sarepta Therapeutics's pipeline?

Sarepta Therapeutics has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Sarepta Therapeutics's portfolio?

Top competitors by shared drug class: Biogen Ma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sarepta.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Sarepta Therapeutics — Portfolio Competitive Intelligence Brief

Sarepta Therapeutics (SRPT) pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

SRPT (NASDAQ) 3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Amondys 45	CASIMERSEN	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	Rare Disease	2021-01-01
Vyondys 53	GOLODIRSEN	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	Rare Disease	2019-01-01
Exondys 51	ETEPLIRSEN	marketed	Antisense Oligonucleotide [EPC]	exon 51 of dystrophin pre-mRNA	Rare Disease	2016-01-01

Therapeutic area mix

Rare Disease · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Biogen Ma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sarepta Therapeutics:

Cite this brief

Drug Landscape (2026). Sarepta Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sarepta. Accessed 2026-05-13.